RLAY Stock Analysis: Buy, Sell, or Hold?
RLAY - Relay Therapeutics, Inc. Common Stock
$17.14
1.26 (7.93%)
▲
5d:
+15.73%
30d:
+31.64%
90d:
+72.96%
HOLD
MODERATE Confidence
Analysis Updated: Jun 18, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Distribution
None View Scanner →
Strength: 7.7/10
Get Alerted When RLAY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: RLAY is 12.1% above its trading range ($15.29). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: RLAY is 12.1% above its trading range ($15.29). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: RLAY is currently trading at $17.14, which is considered extended relative to its 30-day fair value range of $12.99 to $15.29.
Technical Outlook: Technically, RLAY is in a strong uptrend. The price is approaching resistance at $16.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.9% recently.
Market Sentiment: RLAY has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $24.82 (+56.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RLAY is in a strong uptrend. The price is approaching resistance at $16.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.9% recently.
Market Sentiment: RLAY has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $24.82 (+56.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$12.99 -
$15.29
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+12.1% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.9%)
- BULLISH: Trading 56.3% below Wall St target ($24.82)
Trading Range Analysis
30-Day Trading Range
$12.99 -
$15.29
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$12.93
Resistance Level
$16.40
Current Trend
Strong Uptrend
Technical data as of
Jun 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.62
Wall Street Target
$24.82
(+56.3%)
Revenue Growth (YoY)
-60.9%
Share & Embed Analysis
Last updated: June 22, 2026 12:16 PM ET
Data refreshes hourly during market hours. Next update: 1:16 PM
Data refreshes hourly during market hours. Next update: 1:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RLAY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Thomas Catinazzo
SELL
1800 shares
2026-04-09
Thomas Catinazzo
SELL
17717 shares
2026-04-07
Donald A Bergstrom
SELL
2686 shares
2026-01-28
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 60 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 58 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 59 HOLD |
